Results
CIPN
MAY, ADVERSE EVENT
A total of 105 participants, who were enrolled from May 2015 to March 2017 in the screening phase of the pilot study, were included in the retrospective analysis (Participant characteristics (Abbreviations: CIPN, chemotherapy-induced peripheral neuropathy; CTCAE, Common Terminology Criteria for Adverse Events IQR, interquartile range; TSH, thyroid stimulating hormone;.Of the baseline measures, there was a statistically significant correlation between BMI and CIPN severity (odds ratio [OR] 1.08; 95% CI, 1.01-1.16; Univariant analysis of baseline characteristics associated with CIPN severity.Abbreviations: BMI, body mass index CI, confidence interval; CIPN, chemotherapy-induced peripheral neuropathy; OR, odds ratio.There was an association between the cumulative chemotherapy dose and disease-free survival (OR 1.026; 95% CI, 1.00-1.05; 